Other PD-1 monoclonal antibodies, Nivolumab, Cemiplimab, and Tislelizumab, as well as the CTLA4 monoclonal antibody Ipilimumab, are also being evaluated in several clinical trials for MDS (NCT02530463, NCT03017820, NCT06536959, NCT02890329). Here, CTLA4 is linked to myelodysplastic syndrome.